Predictors of long‐term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma.

B Introduction: b Per the CORAL study, response to salvage immunochemotherapy (IC) for patients (pts) diagnosed with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) and high grade B cell lymphoma (HGBL) was predicted by time to relapse, International Prognostic Index (IPI) score and prior receipt of rituximab. Freedom from treatment failure (FFTF) was defined as the interval between receipt of HDC/ASCT and proven/suspected relapse of DLBCL/HGBL or last follow-up (f/u) in remission. Predictors of long-term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma. [Extracted from the article]